News Posts List
Diabetes, Diabetes Drugs, and Cancer Risk
06/10/2011
As early as 1932, physicians noticed an apparent association between type 2 diabetes and increased cancer risk. In recent years, the epidemiological evidence of such an association has mounted steadily—especially with the emergence of large databases, which have allowed us to document the link.
A Phase I Study of Intravenous Recombinant Human IL-15 (rhIL-15) in Adults With Metastatic Melanoma and Metastatic Renal Cell Cancer
06/09/2011
Renal cell cancer patients must either have refused treatment with, have been unable to tolerate, or have experienced progressive disease after treatment with sorafenib or sunitinib and temsirolimus...
WSJ: No, You Can't Keep Your Health Insurance
06/08/2011
A new study by McKinsey suggests that as many as 78 million Americans could lose employer health coverage.
Kidney Cancer Responds Well To A Developing Immunotherapy That Uses Specialized Antibodies
06/08/2011
Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma.
IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
06/08/2011
This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma.
Investigational targeted therapy extends RCC progression-free survival
06/08/2011
"These data, from the first head-to-head phase III study comparing active targeted therapies in advanced RCC, are important for clinicians as they help us advance our understanding of this tumor, where there are limited proven options for previously treated patients," said principal investigator Brian I. Rini, M.D.
SGN-75 Clinical Data at ASCO Annual Meeting
06/07/2011
Among 25 RCC patients treated at escalating doses of SGN-75, two patients achieved a partial response, eight patients had stable disease...
RCC Drugs Market to Reach $3.03 Billion by 2017
06/07/2011
Though just five to six drugs are presently approved, there are many others in the pipeline, including targeted therapies that are expected to make kidney cancer market an active ground for competition in the future.
Cancer-Seeking 'Smart Bombs' Target Kidney Cancer Cells
06/07/2011
Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma.
Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO
06/07/2011
Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis.
News Feed